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A B S T R A C T
Catheter ablation of atrial fibrillation (AF) has been widely accepted as an important 
therapeutic modality for the treatment of patients with symptomatic, drug-refractory 
AF. Ablation strategies which target the pulmonary veins (PVs) and/or the PV an-
trum (segmental or large circumferential lesions) are the cornerstone of AF ablation 
procedures, irrespective of the AF type. Successful electrical PV isolation results in 
maintenance of sinus rhythm in 60 to 85% of patients in patients with paroxysmal AF. 
However, PV isolation is usually insufficient to eliminate persistent or long-lasting 
persistent AF leading to significantly lower success rate of this method. Up to now, 
no single strategy is uniformly effective in patients with persistent and long-lasting 
persistent AF. Many centers follow a stepwise ablation approach including (i) PV iso-
lation as the initial step; (ii) electrogram-based ablation at all sites in the left atrium 
and the coronary sinus exhibiting complex fractionated atrial electrograms; (iii) If 
AF sustains, linear ablation (mainly roof and mitral isthmus lines) is then carried 
out; and (iv) the right atrium and superior vena cava are finally mapped and ablated. 
However, such an extensive ablation strategy lead to longer procedure time, longer 
fluoroscopy time, higher complication rates and higher rates of post-procedural atrial 
tachycardias. Therefore, the risk/benefit ratio of an extensive ablation approach has 
to be carefully evaluated. Catheter ablation of persistent and long-lasting persistent 
AF still remains challenging for the electrophysiologists. The long-term efficacy of 
certain ablation strategies need to be evaluated in randomized trials.
I n T R o d u C T I o n
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical 
practice with an increasing prevalence in relation to age, ranging from 0.1% in people 
younger than 55 years to more than 9% by 80 years of age.1,2 AF is associated with a 2-
fold risk of cardiac and overall mortality.1 In our days, the mainstay of treatment of AF 
remains pharmacological. Data from the AFFIRM,3 the RACE,4 and the PIAF5 trials 
have shown a comparable outcome for both rhythm and rate-control pharmacological 
strategies. However, in subgroup analysis, survival is improved in patients who achieve 
sinus rhythm, an event that is negated by the deleterious effects of the antiarrhythmic 
drugs.6 Thus, the restoration and maintenance of sinus rhythm is of major importance 
if it can be accomplished without the use of antiarrhythmic drugs.
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Catheter ablation of AF has been widely accepted as an 
important therapeutic modality for the treatment of patients 
with symptomatic AF, refractory or intolerant to at least 
one class I or III antiarrhythmic medication.7,8 The current 
AHA/ACC/ESC guidelines state that catheter ablation is a 
reasonable alternative to pharmacological therapy to prevent 
recurrent AF in symptomatic patients with little or no left 
atrial (LA) enlargement (Class: 2A; Level of Evidence: C).2 
However, recent data have clearly demonstated the superiority 
of catheter ablation over antiarrhythmic drug treatment.9-14
Following the pioneering work of Haissaguerre et al. 
electrical isolation of all pulmonary veins (PVs) is the end 
point of ablation for paroxysmal AF.15 Successful PV isolation 
(PVI) results in maintenance of sinus rhythm in 60 to 85% of 
patients.16,17 On the contrary, PVI is insufficient to eliminate 
persistent or long-lasting persistent AF leading to significantly 
lower success rate of this method.7,8,18-19 This difference sug-
gests that the mechanisms underlying the maintenance of 
persistent AF are different in relation to paroxysmal AF.7,8 
Elimination of PV drivers and additional substrate modifica-
tion are required in the setting of persistent and long-lasting 
persistent AF.18-19 Although different ablation strategies have 
been reported for persistent AF, the reproducibility of these 
techniques is considered inconsistent. This review article high-
lights on the current catheter ablation strategies for persistent 
and long-lasting persistent AF.
d e f I n I T I o n  o f  d I f f e R e n T  T y p e S  
o f  A T R I A l  f I B R I l l A T I o n
Based on the updated AHA/ACC/ESC guidelines2, AF 
is classified as paroxysmal, persistent, or permanent. In the 
setting of two or more episodes, AF is designated recurrent. 
If the arrhythmia terminates spontaneously, recurrent AF 
is characterized as paroxysmal. In the case that maintains 
for more than seven days, AF is characterized as persistent. 
Termination with pharmacological therapy or direct-current 
cardioversion does not change the designation. First-detected 
AF may be either paroxysmal or persistent. The category of 
persistent AF also includes cases of long-lasting AF (greater 
than one year) and permanent AF, in which cardioversion 
has failed or has not been attempted. These categories are 
not mutually exclusive in a particular patient, who may have 
several episodes of paroxysmal AF and occasional persistent 
AF, or the reverse.
p A T h o p h y S I o l o g y  
o f  A T R I A l  f I B R I l l A T I o n
The pathophysiology of AF is multifactorial, complex, 
and not well-defined. Up to date, two main theories have 
been reported for the initiation and maintenance of AF. 
The single-focus hypothesis advocates that AF is due to a 
single automatic focus or a microreentrant circuit.2,20 The 
wavefronts emanating from the primary driver circuit (rotor) 
break against regions of varying refractoriness and give rise to 
irregular global activity.2,20 A single focus can fire at a regular 
but very rapid rate that cannot be followed by the rest of the 
atrial tissue, resulting in fibrillatory conduction.20 A variety 
of different potential sources of triggers for AF have been 
reported2; however, triggers that originate from the PVs and 
other thoracic veins appear to be the primary mechanism of 
AF, particularly in subjects with paroxysmal AF.2,15,21 Atrial 
tissue within the PVs in patients with AF display shorter 
refractory period and decremental conduction properties 
compared to control patients leading to a marked heterogene-
ity of conduction that promotes reentry and form a substrate 
for sustained AF.2,7,8
The multiple re-entrant wavelet hypothesis as a mechanism 
of AF was described by Moe and colleagues in 1959,2,22 with 
supportive experimental work by Alessie.23 This theory was 
the premise on which Cox’s Maze procedure was developed 
and provides the rationale for ablation procedures leading to 
LA compartmentalization.24 The multiple re-entrant wavelet 
hypothesis supports that fractionation of wavefronts propa-
gating through the atria results in self-perpetuating ‘daughter 
wavelets’. Multiple re-entrant wavelets are separated by lines 
of functional conduction block. The lines of the conduction 
block can occur around the anatomical structures within the 
atria with different inherent electrophysiological properties, 
such as scars, patchy fibrosis and myocardium, at different 
stages of recovery and excitability. The number of wavelets at 
any given time depends on the conduction velocity, atrial mass 
and refractory period in different parts of the atria. Thus, AF 
is perpetuated by slowed conduction, increased atrial mass 
and shorter refractory periods.
The relationship between these mechanisms is complex, 
and they often coexist in the same patient, particularly in 
the setting of persistent AF or long-lasting persistent AF.25 
In addition to these models, the role of the local autonomic 
nervous system in the initiation and perpetuation of AF 
has been demonstrated in both animal and human models. 
Parasympathetic ganglionated plexi (GP) are located near 
the PV-LA junction and may be important targets for abla-
tive therapy.7,8 Autonomic factors have also been implicated 
in the generation of complex fractionated atrial electrograms 
(CFAEs), an important substrate of AF.7,8
Progressive electroanatomic remodeling that develops as 
AF progresses from paroxysmal to persistent and permanent 
has been well demonstrated to further facilitate AF.26 Atrial 
dilation, interstitial fibrosis, uncoupling of the myofibrils, loss 
of myofibrils, deposition of extracellular matrix, loss of gap 
junctions, resultant anisotropy, conduction slowing and/or 
block, and shortening of the effective refractory period may 
ATRIAL FIBRILLATION ABLATION
175
facilitate reentry, which is critical to perpetuation of AF.2,7,8 
As a result of progressive electroanatomic remodeling, mecha-
nisms other than PV arrhythmogenicity are strongly involved 
and perpetuate AF.
A B l A T I o n  S T R A T e g I e S  A n d  S u C C e S S 
R A T e S  I n  p e R S I S T e n T  A f
1 .  p u l m o n A R y  v e I n  I S o l A T I o n
Ablation strategies which target the PVs and/or the PV 
antrum are the cornerstone of AF ablation procedures, ir-
respective of the AF type. Initial attempts were targeted 
the arrhythmogenic activity within the PVs using a focal 
approach.15 Due to the high risk of PV stenosis and the high 
rate of recurrence, complete electrical isolation of the PVs 
by segmental ostial ablation quickly replaced the initial ap-
proach.27,28 Successful PV isolation was defined by loss of PV 
potentials (entrance block) and failure to capture left atrium 
during pacing from the PV (exit block). Figure 1 shows an 
example of electrical isolation of the left superior PV in a 
patient with persistent AF. A clinically satisfactory result can 
be achieved in more than 80% of patients with paroxysmal 
AF using a segmental PVI approach.27,28 However, this ap-
proach had minimal efficacy in patients with persistent AF.27,28 
Pappone et al. introduced the circumferential PV ablation 
without PV isolation with higher success rate even in patients 
with persistent and permanent AF.29 This technique involves 
applications of radiofrequency energy 1-2 cm away from the 
ostia of the PVs. The PV ostium is identified by a combina-
tion of venography, electrogram, and the drop-off site of the 
mapping catheter during its withdrawal from the vein. Each 
target site is usually ablated until the local electrogram am-
plitude decreased by ≥80% or to <0.1 mV. Lemola et al. have 
additionally shown that complete electrical isolation of the PVs 
is not a requirement for a successful outcome after left atrial 
circumferential ablation.30 In a randomized trial, Arentz et al. 
have demonstated that isolation of a large circumferential area 
around both ipsilateral PVs with verification of conduction 
block is a more effective treatment of AF than isolation of each 
individual PV using a segmental approach.31 Figure 2 shows 
the three-dimensional reconstruction of the left atrium with 
large circumferential ablation lesions around both ipsilateral 
veins and additional ablation lines on the interpulmonary 
isthmus creating a “figure of eight” model. Up to now, PVI 
or PV antral isolation confirmed by absence or dissociation 
of PV potentials is the most effective strategy for treatment 
of most patients with paroxysmal AF.32-34 Despite achieving 
a very high rate of electrical PVI, PVI strategies alone have 
consistently demonstrated a lower success rate in patients with 
persistent AF compared to paroxysmal AF.7,8,35-37
fIguRe 1. Left superior PV isolation in a patient with persistent AF. Map indicates distal bipole of the ablation catheter; PV indi-
cates Lasso catheter bipoles.
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2 .  l I n e A R  A B l A T I o n
As previously stated, PVI alone is insufficient for restora-
tion and maintenance of sinus rhythm in most patients with 
persistent AF. Based on the high success rates of surgical 
MAZE procedures,24 several attempts have been made to 
reproduce these results by percutaneous catheter-based linear 
ablations. Linear lesions usually include a roof line connecting 
the left and right superior PVs (Figure 3), and a mitral line 
connecting the mitral annulus to the left inferior PV (Figure 
3 and Figure 4).35-38 Addition of linear lesions is intended to 
modify the arrhythmogenic LA substrate and atrial macro-
re-entrant circuits involved in maintenance of AF.35-39 Linear 
lesions have been associated with conversion of AF either 
directly to sinus rhythm or to atrial tachycardia (AT), demon-
strating that such lesions significantly modify the substrate for 
AF.39 Linear lesions applied at the mitral isthmus or the roof of 
the LA increase the AF cycle length by a mean of 20 ms, and 
exert a favourable impact on elimination of AF.38 Bidirectional 
block across the linear lines has to be confirmed in order to 
assess completeness of linear lesions.38,39 However, LA linear 
ablation still remains technically challenging. In the study of 
Jais et al, 68% of patients required an ablation within the CS 
facing the endocardial aspect of the mitral isthmus because 
of persisting epicardial conduction.38
fIguRe 2. Three-dimensional reconstruction of the left atrium 
using the CARTO 3 map system (Biosence-Webster, Johnson & 
Johnson, USA) showing large circumferential ablation lesions 
around both ipsilateral veins. In this example, additional radi-
ofrequency energy was applied on the interpulmonary isthmus 
following the large circumferential lesion creating a “figure of 
eight” model.
fIguRe 3. Three-dimensional reconstruction of the left atrium 
using the CARTO 3 map system (Biosence-Webster, Johnson & 
Johnson, USA) showing large circumferential ablation lesions 
around both ipsilateral veins and extensive ablation lines includ-
ing roof, mitral isthmus and coronary sinus line. This figure also 
shows right superior PV (RSPV) isolation and an example of 
CFAEs recorded within the coronary sinus (CS).
ATRIAL FIBRILLATION ABLATION
177
Willems et al. have investigated the effectiveness of ad-
ditional substrate modification by left atrial linear lesions as 
compared with PVI alone in patients with persistent AF in a 
prospective randomized study.40 After a mean follow-up time 
of 487 days, only 20% of patients undergoing stand alone PVI 
remained in sinus rhythm when compared with 69% follow-
ing PVI combined with substrate modification. This study 
clearly shows that PVI alone is insufficient for the treatment 
of patients with persistent AF. In a similar study, Fassini et 
al. confirmed the additional benefit of mitral isthmus abla-
tion in patients with persistent AF.41 Yao et al. attempted to 
convert AF to sinus rhythm using a linear catheter ablation 
approach.42 This approach initially utilized a figure of seven 
lesion line between the right and left superior PV on the roof 
of the left atrium and then extended along the ridge between 
the left appendage and the left PVs until the mitral valve 
annulus, as the primary lesions. AF was converted to sinus 
rhythm in 81.6% of patients (90.8% of paroxysmal and 51.1% 
of persistent AF) with this technique. During a mean follow-
up of 18.2 months follow-up, 88.3% of patients were free of 
atrial tachyarrhythmias without medication.
3 .  C o m p l e x - f R A C T I o n A T e d  A T R I A l 
e l e C T R o g R A m S
CFAEs areas represent potential AF substrate sites and 
are now considered as important targets for AF catheter abla-
tion.7,8 CFAEs indicate sites of slow conduction, wavefront col-
lision, conduction block, or anchor points for reentrant circuits 
based on the findings of an epicardial unipolar mapping study 
in humans.43 CFAEs have also been proposed to indicate sites 
of ganglionated plexi, as shorter effective refractory period at 
these sites would allow higher-frequency activation.44 CFAEs 
are defined as (i) atrial electrograms that are fractionated 
and composed of two or more deflections averaged over a 
10-s recording period; and (ii) atrial electrograms with a very 
short cycle length (≤120 ms) with or without multiple potentials 
when compared with the atrial cycle length recorded from 
other parts of the atria.45 End points for ablation at sites of 
CFAEs include complete elimination of CFAEs or slowing and 
organization of local electrograms.45,46 An example of CFAEs 
is showing in Figure 3. The preferential sites of AF termina-
tion or regularization have been found around the pulmonary 
veins, at the anterior wall of the LA and at the interatrial 
septum. Nademanee et al. have shown that demonstrated 
that ablation of CFAEs alone resulted in termination of AF 
without external cardioversion in 95% of patients persistent 
or paroxysmal AF and at 1-year follow-up, 91% of patients 
were free of arrhythmia and symptoms.45 On the contrary, 
Oral et al. have demonstrated a modest short-term efficacy of 
the ablation procedure when targeting only the CFAEs.46 In 
particular, only 33% of patients were in sinus rhythm without 
the use of antiarrhythmic drugs after the index ablation.46 
Bencsik et al. have recently demonstrated that CFAEs ablation 
guided by a dedicated software algorithm and performed after 
circumferential PVI outside of the circular PVI lines had no 
significant impact on the fibrillatory process and displayed a 
minor role in achieving higher rates of termination and non-
inducibility in patients with persistent AF.47
Ablation of CFAE as a stand-alone ablation strategy seems 
insufficient for the treatment of patients with persistent AF.48 
A combined approach of PVI and CFAE ablation in persistent 
AF leads to acute AF termination in 66% and long-term main-
tenance of sinus rhythm in 74% of cases.49 The role of ablation 
of CFAEs following PV antral isolation was investigated in 
two recent randomized studies. Elayi et al. have conducted a 
multicenter, randomized controlled study of three different 
catheter ablation strategies in patients with long-lasting per-
sistent AF (≥1 year, median duration 28 months): anatomic 
circumferential PV ablation, electrophysiologically guided 
PV antral isolation, and ablation of complex fractionated 
atrial electrograms (right and left atria and coronary sinus) 
followed by PV antral isolation (CFAE plus PV antral isola-
tion). CFAE plus PV antral isolation (61%) outperformed PV 
antral isolation (40%), which was superior to circumferential 
PV ablation (11%).50 Oral et al. randomized 119 consecutive 
patients with long-standing persistent AF to PVAI or PVAI 
and further CFAE ablation. These authors found that up to 
2 h of additional ablation of CFAEs after PVAI does not ap-
pear to improve clinical outcomes in patients with long-lasting 
persistent AF.51
4 .  n o n - p u l m o n A R y  v e I n  f o C I
Although the PVs are a dominant source of AF, non-PV 
ectopic activity can trigger AF, and ablation of these ectopic 
activities can eliminate AF in a specific group of patients. 
Non-PV triggers are more commonly observed in patients 
with persistent (8.2%) and long-lasting persistent AF (19.1%) 
in relation to those with paroxysmal AF (2.9%).52 Ablation of 
fIguRe 4. Mitral isthmus line connecting the mitral valve (MV) 
annulus to the left inferior PV (LIPV).
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non-PV foci following PVI can organize persistent AF into 
focal or macro-re-entrant atrial tachycardias, which can be 
eliminated, resulting in maintenance of sinus rhythm in the 
majority of patients.53,54 The majority of non-PV foci respon-
sible for initiation of AF are located in the superior vena cava, 
crista terminalis, coronary sinus, LA free wall, LA appendage 
and ligament of Marshall.53,54
5 .  A u T o n o m I C  g A n g l I o n A T e d  p l e x I
Experimental and clinical data suggest that activation of 
the autonomic nervous system may play a critical role in the 
initiation and maintenance of AF.55 The majority of GPs are 
located over the LA and in fat pads at the superior vena cava-
aorta and the PV-LA junctions, and ablation of these sites can 
effectively denervate the LA.56 GP activation includes both 
parasympathetic and sympathetic stimulation of the atrium 
surrounding the GP and the closest PV. Parasympathetic 
stimulation markedly shortens action potential duration, while 
sympathetic stimulation increases calcium loading and calcium 
release from the sarcoplasmic reticulum leading to early af-
terdepolarizations and triggered activity.57,58 GPs can be easily 
mapped using high-frequency stimulation. Vagal denervation 
after circumferential PV ablation was associated with a higher 
probability of maintenance of sinus rhythm.59 Limited data ex-
ist regarding GP ablation in AF, particularly in persistent AF. 
It is unclear whether ganglionated plexi should be specifically 
targeted, given that these sites may be concomitantly ablated 
in the course of above described ablation targets.
C o m B I n A T I o n  o f  A B l A T I o n 
T e C h n I q u e S :  T h e  B o R d e A u x 
e x p e R I e n C e
According to the Bordeaux group,18,19,34,36,60,61 catheter 
ablation sequence for persistent AF should be as follows: (i) 
PV isolation is the initial step aiming at elimination of PV elec-
trograms; (ii) Electrogram-based ablation is then performed at 
all sites in the LA and the CS exhibiting any of the following 
electrogram features: (a) CFAEs, especially continuous activ-
ity; (b) activation gradient of at least 70 ms between the distal 
and proximal recording bipoles of the mapping catheter; (c) 
frequency gradient in regions with a cycle length shorter than 
the mean LA appendage cycle length. The endpoint of electro-
gram-based ablation is transformation of complex fractionated 
electrograms into discrete electrograms and slowing of the 
local cycle length compared with LA appendage cycle length 
or finally elimination of electrograms; (iii) If AF sustains 
following PV isolation and electrogram-based ablation, linear 
ablation is carried out. The roof line is primarily performed 
followed by the mitral line if AF persists. During AF, the 
endpoint of linear ablation is significant reduction or aboli-
tion of the local electrograms on the line. After restoration 
of sinus rhythm, bidirectional block across the linear lines is 
confirmed in order to assess completeness of linear lesions; 
(iv) Finally, the right atrium (RA) and superior vena cava are 
targeted for ablation if implicated as a source perpetuating 
AF and only after all LA ablation steps. The perpetuating 
influence of the RA is likely when RA appendage cycle length 
is shorter than the LA appendage cycle length by more than 
20 ms after completion of LA ablation. Using this sequential 
ablation, the Bordeaux group reported termination of chronic 
AF (including patients with persistent AF) by conversion to 
either sinus rhythm or atrial tachycardia in 87% of patients 
during the index procedure and freedom from AF after an 
11-month follow-up period in 95% of patients.18,19 Interestingly, 
AF was terminated in only 5% of patients by PVI, in 60% after 
electrogram-based ablation, and in 84% following linear abla-
tion.18 AF cycle length was the strongest independent predictor 
of procedural AF termination.61 A recent systematic review of 
the literature with regards to the impact of ablation technique 
on the outcomes of persistent and long-lasting persistent AF 
ablation showed a significant variation in success rates sug-
gesting that the optimal ablation technique is unclear.62 Table 
1 summarizes the main findings of this systematic review.
TABle 1. The impact of ablation technique on the outcomes 
of persistent and long-lasting persistent AF ablation.62
Ablation technique 
Success 
rate
Segmental PVI 21-22%
Circumferential PV antrum ablation with electrical 
isolation 
38-40%
Circumferential PV antrum ablation without 
electrical isolation
37-56%
Linear ablation in addition to PV antrum ablation 11-74%
Linear ablation in addition to PV antrum isolation 38-57%
CFAEs ablation alone 24-63%
CFAEs ablation as an adjunct to PV antrum 
ablation 
50-51%
CFAEs ablation as an adjunct to PV antrum 
isolation 
36-61%
CFAEs ablation as an adjunct to PV antrum 
isolation and linear ablation 
68%
A combination ablation approach 38-62%
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e n d - p o I n T S  o f  C A T h e T e R  
A B l A T I o n  f o R  p e R S I S T e n T  A f
The goal of catheter ablation in persistent AF is trigger 
elimination and substrate modification. However, there is no 
clear end-point for persistent AF ablation. Four procedural 
end-points are accepted for AF catheter ablation: (i) electri-
cal PVI; (ii) completion of a predetermined linear lesion; (iii) 
termination of AF during ablation; and (iv) non-inducible AF 
after ablation.7,8,33,34 Although restoration of sinus rhythm 
by ablation appears an intuitively ideal end point, data are 
limited to support such an end-point. In a prospective study 
of 153 patients who underwent catheter ablation of persistent 
AF, a lower incidence of AF recurrence was demonstrated 
in those patients in whom AF was terminated during the 
index procedure compared to those without termination (5 
vs. 39%, mean follow-up 32+11 months).60 During ablation 
of persistent AF with various strategies, the arrhythmia often 
organizes into a regular AT and sometimes even terminates 
into sinus rhythm.18 In a recent prospective study, Elayi et al. 
assessed the AF termination mode during catheter ablation 
in 306 patients with long-lasting persistent AF and whether it 
predicts long term sinus rhythm maintenance.63 During AF 
ablation, only 6 out of 306 patients converted directly to sinus 
rhythm and 172 patients organized into AT. The presence or 
absence of organization during ablation clearly predicted the 
predominant mode of recurrence, respectively AT or AF. 
Authors showed that AF termination during ablation (conver-
sion to AT or sinus rhythm) predict the mode of arrhythmia 
recurrence (AT vs. AF), but did not impact on long term 
sinus rhythm maintenance after a single or two procedures. 
Non-inducibility of AF following catheter ablation seems to 
be associated with an improved outcome. However, there is 
no current consensus on the definition of non-inducibility and 
the induction protocol used.
In clinical practice, the ideal end-point for AF catheter 
ablation is freedom from AF without the use of antiarrhythmic 
medications. There is much controversy regarding the moni-
toring period as well as the minimum acceptable AF burden. 
Current definitions of freedom from AF include absence of 
AF, AF episodes lasting up to 30s, and absence of symptomatic 
AF.7,8,33 A ‘blanking period’ of up to 3 months after ablation, 
during which antiarrhythmic medications may be continued 
and direct current cardioversion can be performed for early 
recurrences of arrhythmias, appears to be adequate in order 
to access the efficacy of an ablation strategy.7,8 However, clear 
definitions of freedom from AF and the ‘blanking period’ are 
needed in order to be able to compare and interpret the results 
of different AF ablation trials.
w h I C h  I S  T h e  p R I C e  f o R  A n 
e x T e n S I v e  A B l A T I o n  p R o C e d u R e  I n 
T h e  S e T T I n g  o f  p e R S I S T e n T  A f ?
Longer procedure time, longer fluoroscopy time, higher 
complication rates and high rates of post-procedural ATs are 
the main consequences of an extensive ablation procedure car-
ried out in the setting of persistent and long-lasting persistent 
AF. In a recent systematic literature review of studies with per-
sistent and long-lasting persistent AF ablation, complications 
have been reported in 4.4% of patients.62 Death is an uncom-
mon complication of AF ablation, occurring in 0.1-0.15% of 
subjects.64,65 These fatal events have been related to different 
steps of the ablation procedure including the transseptal punc-
ture, a prolonged catheter manipulation in the left atrium, and 
a high cumulative RF energy delivered in the left atrium in 
the context of a high level of systemic anticoagulation. Cardiac 
tamponade is by far the most common fatal complication of 
AF ablation.7,8,62,64,65 In a recent worldwide survey on the safety 
of catheter ablation of AF including 16.309 patients, there were 
213 episodes of tamponade (1.31%), 37 strokes (0.23%) and 
115 transient ischemic attacks (0.71%).64 PV stenosis requir-
ing intervention was observed in 0.29% of patients.64 Femoral 
pseudoaneurysm and artero-venous fistulae were observed in 
0.92% and 0.54% of patients, respectively.64 Atrio-esophageal 
fistulas, esophageal damage, and perforation are rare, but 
usually fatal complications of AF ablation (0.04%).64 Finally, 
transient ST-segment elevation, usually in inferior leads, is 
rarely observed during AF ablation and has been related to 
coronary artery spasm secondary to autonomic modulation or 
air emboli.66 ATs following AF ablation are a rapidly growing 
clinical problem due to the expansion of the ablation strategies 
in the setting of persistent AF.7,8,64,65 These secondary ATs 
are often incessant and very poorly tolerated by the patient. 
ATs have been shown to occur in about 40% of patients who 
undergo the stepwise ablation approach.18
We have recently shown that peri-procedural maintenance 
of sinus rhythm lead to similar success rates in patients with 
paroxysmal and persistent AF.67 After a relatively long follow-
up period (18±10 months), 70.1% of patients with paroxysmal 
and 68.5% with persistent AF were in sinus rhythm without 
antiarrhythmic drugs. The peri-procedural maintenance of 
sinus rhythm (“sinus rhythm begets sinus rhythm” theory) 
may contribute to this improved success rate in the setting 
of persistent AF possibly by facilitating reversed LA remod-
eling. In addition, the acceptable long-term efficacy of large 
circumferential electrical PVI around both ipsilateral PVs in 
the setting of persistent AF may be explained by the adequate 
LA substrate modification following these lesions. As shown 
in Figure 5, arrhythmogenic ostial foci, parasympathetic in-
nervation (GPs), and CFAEs that are possible mechanisms for 
the initiation and perpetuation of AF may be concomitantly 
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ablated in the course of these large circumferential lesions. 
This study shows that a less extensive ablative approach has 
favourable long-term efficacy in the setting of persistent 
AF.67 A similar approach is taking place in our Laboratory at 
Evagelismos Hospital, where large circumferential lesions are 
performed during sinus rhythm in all patients with paroxysmal 
and persistent AF using the CARTO™ 3 3-D mapping system 
(Biosense Webster, Inc., CA, USA). CFAEs ablation and/or 
linear lesions are performed in the setting of long-lasting 
persistent AF (>12 months AF).
e v o l v I n g  A B l A T I o n  T e C h n o l o g I e S
A number of technical advances regarding mapping 
systems as well as catheter designs and energy sources are 
tacking place playing a major role on AF ablation, and more 
are expected. Fluoroscopy-guided catheter manipulation in 
the LA requires extensive previous experience and carries a 
higher risk of complications. The use of 3-D mapping systems, 
with or without intracardiac echocardiography, facilitates real-
time assessment of LA anatomy, and can help operators to 
target the ablation sites. The Carto™ XP (Biosense Webster, 
Inc., CA, USA) and NavX™ (St Jude Medical, Inc., MS, USA) 
are the most known 3-D mapping systems used in clinical 
practice.33 Both of them provide an accurate electroanatomic 
map facilitating the ablation procedure and minimizing fluor-
oscopy and procedural times. A randomized trial has recently 
shown that the three-dimensional magnetic resonance imaging 
of the LA reconstruction merged with the electroanatomical 
map does not significantly improve the clinical outcome, but 
significantly shortens the X-ray exposure.68 Two relatively new 
remote navigation systems are now available for clinical use: 
the magnetic navigation system (Niobe II system, Stereotaxis, 
Inc., MO, USA) and the robotic navigation system (Sensei 
system, Hansen Medical, Inc., CA, USA).69-72
Traditional catheter ablation is performed in a single-tip, 
point-by-point ablation process. This technique requires a 
high degree of operator skill and procedures are long-lasting, 
often more than 4 hours. New catheter designs and energy 
sources for ablation are now under active investigation. The 
PVAC multipolar circular mapping and ablation catheter 
(Medtronic, Ablation Frontiers, Inc., Carlsbad, CA, USA) 
is a relatively new catheter that delivers both duty cycled 
bipolar and unipolar radiofrequency energy at a relatively 
low power through multiple electrodes at once, potentially 
making it faster and easier to isolate the PVs. This catheter 
has a bidirectional steering mechanism and an over-the-wire 
design. Initial studies have shown that PV isolation can be 
effectively and safely accomplished using the duty-cycled 
unipolar/bipolar RF ablation catheter.73-75 The Mesh catheter 
(Bard Electrophysiology, Inc., MA, USA) consists of an ex-
pandable, braided-wire, electrode array, designed to perform a 
high-density, 36-electrode (18 bipoles) mapping and to deliver 
radiofrequency by the same electrodes.76-77 Once the ostium is 
reached, RF energy is delivered to the annular perimeter of 
the umbrella-shaped catheter. The circumferential exposed 
wire segment is divided into four quadrants, each containing 
a thermocouple at its central point, allowing RF delivery in 
a temperature control mode. The safety and efficacy of the 
Mesh system in both mapping and ablating the PVs have been 
reported. The success rate for PV isolation varies between 63% 
and 100%.77 No procedure related complications occurred us-
ing this type of catheter.77,78 Long-term results of the clinical 
efficacy of this system need to be further evaluated.
Balloon-ablation catheters have emerged as promising new 
technology that may allow rapid and effective isolation of all 
PVs. Cryoballoon ablation appears to be the most completely 
tested. The cryoballoon system is a deflectable catheter (Cryo-
cath Technologies Inc., Quebec, Canada; Medtronic Inc., MN, 
USA) with a balloon-within-a-balloon design wherein the cryo 
refrigerant (N2O) is delivered within the inner balloon.78 The 
balloon is inflated at each PV ostium to temporarily occlude 
blood flow from the targeted PV. Tissue injury by freezing oc-
curs due to direct cellular damage as well as microcirculatory 
failure shortly after tissue thawing. The prime mechanism of 
cell death is formation of intracellular ice crystals at rapid 
freezing rates, which occurs only close to the cryoballoon, 
highlighting the need for good tissue contact. Initial trials 
have demonstrated efficacy similar to radiofrequency ablation 
with limited applications and reduced procedure times.79-82 
An uncommon, but important complication of this system is 
right phrenic nerve paralysis.79-82 Other novel energy sources 
for ablation include high-intensity ultrasound and laser abla-
fIguRe 5. Arrhythmogenic ostial foci (PV), parasympathetic 
innervation (GPs), and CFAEs are possible mechanisms for the 
initiation and perpetuation of AF and can be concomitantly ab-
lated in the course of large circumferential lesions.
ATRIAL FIBRILLATION ABLATION
181
tion. The high-intensity focused ultrasound (HIFU) balloon 
catheter (ProRhythm Inc., Ronkonkoma, NY, USA) uses a 
focused ring of ultrasound energy to ablate myocardial tissue.74 
Borchert et al. have shown that treatment with the HIFU abla-
tion system led to an increased incidence of atrio esophageal 
fistula.83 As a result, all clinical trials with the ProRhythm 
focused ultrasound ablation system have now been terminated. 
The CardioFocus (Marlborough, MA, USA) ablation system is 
a balloon-based laser ablation.78 Limited data are available on 
the outcomes of AF ablation using this energy source.78 Large 
studies will be needed to determine the safety and efficacy of 
the CardioFocus laser balloon ablation system.
C o n C l u S I o n S
In conclusion, catheter ablation of persistent and long-last-
ing persistent AF remains challenging for the electrophysiolo-
gists. Up to now, no single strategy is uniformly effective in 
patients with persistent AF. The risk/benefit ratio of an ex-
tensive ablation approach has to be carefully evaluated. More 
lesions prolong not only procedure and fluoroscopic times, 
but also increase the risk of complications including ATs. For 
this purpose, the long-term success rates of certain ablation 
strategies need to be evaluated in randomized trials.
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